PATIENT PREFERENCE-BASED UTILITY WEIGHTS FROM THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL (FACT-G) IN WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER RECEIVING LETROZOLE PLUS LAPATINIB OR LETROZOLE ALONE

被引：5
|
作者：
Delea, T. E. [1 ]
Sofrygin, O. [1 ]
Amonkar, M. [2 ]
机构：
[1] PAI, Brookline, MA USA
[2] GlaxoSmithKline Inc, Philadelphia, PA USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72194-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A43 / A44
页数：2
相关论文
共 50 条
  • [21] The EXpand Study - Effect of Zoledronic Acid on Prevention of Bone Loss, During Extended Adjuvant Therapy With Letrozole in Postmenopausal Women With Primary Hormone Receptor Positive Breast Cancer Compared to Letrozole Alone
    Hellriegel, M.
    Mueller, M.
    Reimer, T.
    Baerens, D. T.
    von der Assen, A.
    Hackmann, J.
    Schmidt, K.
    Baier-Ebert, M.
    Spall, T.
    Emons, G.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S390 - S390
  • [22] Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib
    Sherrill, Beth
    Sherif, Bintu
    Amonkar, Mayur M.
    Maltzman, Julie
    O'Rourke, Lisa
    Johnston, Stephen
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (12) : 2245 - 2252
  • [23] United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument
    King, Madeleine T.
    Revicki, D. A.
    Norman, R.
    Mueller, F.
    Viney, R. C.
    Pickard, A. S.
    Cella, D.
    Shaw, J. W.
    PHARMACOECONOMICS-OPEN, 2024, 8 (01) : 49 - 63
  • [24] Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).
    Tan, Antoinette R.
    Wong, Serena Tsan-Lai
    Warren, Robert D.
    Eng-Wong, Jennifer
    Liu, Minetta C.
    Zelnak, Amelia Bruce
    Lin, Yong
    Shih, Weichung
    Ganesan, Shridar
    Grana, Generosa
    Isaacs, Claudine
    Toppmeyer, Deborah
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument
    Madeleine T. King
    D. A. Revicki
    R. Norman
    F. Müller
    R.C. Viney
    A. S. Pickard
    D. Cella
    J. W. Shaw
    PharmacoEconomics - Open, 2024, 8 : 49 - 63
  • [26] MIRACLE study (CBCSG016): A randomized phase II study of letrozole versus letrozole plus everolimus for hormone receptor positive premenopausal women with recurrent or metastatic breast cancer on goserelin treatment after progession on tamoxifen.
    Xu, Binghe
    Liu, Donggeng
    Lu, Jinsong
    Ouyang, Tao
    Li, Xiang
    Fan, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Relevance of serum HER2 extracellular domain (sECD) in EGF30008, a study of letrozole ± lapatinib in patients (pts) with hormone-receptor positive (HR plus ) metastatic breast cancer (MBC)
    Platek, G. T.
    Koehler, M.
    Gagnon, R.
    O'Rourke, L.
    Maltzman, J. D.
    Press, M.
    Johnston, S.
    Pegram, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED/METASTATIC BREAST CANCER FROM A UK NATIONAL HEALTH SERVICE PERSPECTIVE
    Hettle, R.
    Suri, G.
    Misty, R.
    Chandiwana, D.
    Lee, A.
    VALUE IN HEALTH, 2017, 20 (09) : A433 - A433
  • [29] Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India
    Loi, Sherene
    Karapetis, Christos S.
    McCarthy, Nicole
    Oakman, Catherine
    Redfern, Andrew
    White, Michelle
    Khasraw, Mustafa
    Doval, Dinesh Chandra
    Gore, Vinod
    Alam, Mahmood
    Binko, Justin
    Lu, Dongrui Ray
    Kim, Sindy
    Boyle, Frances
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (06) : 560 - 569
  • [30] First-line lapatinib combined with letrozole versus letrozole alone for hormone receptor positive (HR plus ) metastatic breast cancer (MBC): Subgroup analyses of borderline FISH+, IHC 2+, HER2 unknown (UNK), and treatment-naive (TN) populations from EGF30008
    O'Rourke, L.
    Pegram, M.
    Press, M.
    Pippen, J.
    Pivot, X.
    Gomez, H.
    Florance, A.
    Maltzman, J.
    Johnston, S.
    Johnston, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345